Titration Schedules: Why Dose Ramps Are Built the Way They Are

Anyone who has looked into GLP-1 medications for weight management has probably noticed the same pattern: nobody starts at the dose they'll eventually take. Instead, the dose goes up in steps over weeks or months. That's not a marketing pace or a way to stretch out a subscription. It's called titration, and it follows a specific, tested schedule for a specific reason.

What titration actually means

Titration is the practice of starting a medication at a low dose and raising it at fixed intervals until reaching a target maintenance dose, or stopping earlier if the person doesn't tolerate a higher amount. For weekly GLP-1 injections, that usually means a new, higher dose every four weeks rather than jumping straight to the amount a person will eventually take long-term.

The FDA-approved prescribing information for semaglutide injection lays this out as a table, not a suggestion. The label sets an initiation dose for the first four weeks, then raises the dose every four weeks after that, with the maintenance dose reached only in week 17 or later. Tirzepatide, a related GLP-1/GIP medication, has the same shape in its own approved labeling: a starting dose held for four weeks, then increases of a fixed increment after at least four weeks at the current dose, until a prescriber settles on one of several approved maintenance doses.

Why the slow ramp exists

The reason isn't caution for its own sake. It's tolerability. The semaglutide label notes that the medication delays gastric emptying, and lists nausea, diarrhea, vomiting, and constipation among the most common adverse reactions reported in its trials. Those are the reactions the escalation schedule is designed around.

The regulatory record says this outright. The FDA-approved labels for both semaglutide and tirzepatide state that the escalation schedule is there to reduce the risk of gastrointestinal adverse reactions, and the semaglutide label reports that those reactions were most frequently reported during dosage escalation rather than later.

The trial record matches. In SURMOUNT-1, a 72-week trial of tirzepatide in 2,539 adults, gastrointestinal events were the most common adverse events, most were mild to moderate, and the published results describe them as occurring primarily during dose escalation. Adverse events led 4.3% to 7.1% of participants on tirzepatide to stop treatment, against 2.6% on placebo.

The semaglutide label also says what to do when a step goes badly. If a patient does not tolerate a dose during escalation, it tells the prescriber to consider delaying the next increase by four weeks. Waiting is part of the schedule, not a departure from it.

The schedule comes from the label, not preference

It's worth being specific about who sets the schedule. For an FDA-approved product like semaglutide injection, the dosing table is part of the approved labeling: four weeks at the starting dose, then a step up every four weeks, continuing until the recommended maintenance dose. That timeline isn't something a patient or a clinic decides case by case. It's the schedule that was studied and approved.

The STEP 1 trial of semaglutide followed 1,961 adults with obesity or overweight for 68 weeks and reported a mean body-weight change of 14.9% against 2.4% on placebo. Those 68 weeks contain the labeled 16-week climb as well as the maintenance period, so the studied result covers the whole arc, ramp included, rather than maintenance dosing on its own.

That distinction matters for compounded formulations too, since some telehealth programs, including the MEDGm program, prescribe compounded semaglutide or tirzepatide rather than the brand-name product after a clinical evaluation. Compounded semaglutide and tirzepatide are not FDA-approved products, and the schedule a compounding pharmacy or prescriber uses may differ from the studied brand-name timeline. That's a real distinction worth understanding before comparing programs, not a technicality.

Anyone wanting the fuller picture of how GLP-1 dosing and titration actually work can find it explained plainly in Health Stacker's GLP-1 guide collection.

Not everyone reaches the top dose

The highest dose in a product's labeling is not a requirement for every patient. For weight reduction, the semaglutide label lists two maintenance doses, a recommended one and a lower one, and tells the prescriber to weigh treatment response and tolerability when choosing between them. The tirzepatide label says much the same: if a patient does not tolerate a maintenance dosage, consider a lower one. Staying at a lower step is written into both documents rather than treated as a failure of the schedule.

Programs built around GLP-1 therapy, including telehealth options that provide compounded semaglutide or tirzepatide after a clinical evaluation, generally build in scheduled follow-ups, often around every 12 weeks, specifically so a provider can review how the titration is going and adjust it if needed. If someone is looking into the MEDGm program page, that follow-up structure is part of what a subscription typically includes, along with dose adjustments as the person moves through the schedule. It's worth noting MEDGm's program isn't available in Louisiana, where compounded GLP-1 medication for weight loss is prohibited, and that it excludes patients under 19 in Nebraska.

Who the schedule is written for

The semaglutide label addresses missed doses directly. If two or more consecutive weekly doses are missed, it says to resume dosing as scheduled or, if needed, reinitiate the medication and follow the escalation schedule again, noting that doing so may reduce the gastrointestinal symptoms that come with restarting treatment. Two options, and a judgment call about which one fits. That judgment sits in a document written for prescribers, in a dosing section that assumes a clinician is reading it.

That is what people mean when they call titration a supervised process. The schedule, the pace, and any adjustment to either are decisions a patient and a licensed provider make together, based on how the medication is actually being tolerated, rather than something to work out from a label or a forum post.

Sources

• Wegovy (semaglutide) injection, FDA prescribing information, revised 08/2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf. Weight reduction in adults and patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition; separate indications cover cardiovascular risk reduction and noncirrhotic MASH. Subcutaneous semaglutide, once weekly, ongoing. Table 1 sets a 16-week initiation and escalation schedule (0.25 mg for weeks 1 through 4, then 0.5, 1, and 1.7 mg in four-week steps), with maintenance dosing from week 17. Endpoint: the label states the schedule exists to reduce the risk of gastrointestinal adverse reactions, reports those reactions as most frequently reported during escalation, tells prescribers to consider delaying escalation by four weeks when a dose is not tolerated, lists either of two maintenance doses for weight reduction, and gives two options after two or more missed consecutive doses. Limitation: applies only to this FDA-approved product; compounded formulations are not FDA-approved and may follow different schedules.
• Zepbound (tirzepatide) injection, FDA prescribing information, revised 01/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf. Adults with obesity or overweight plus a weight-related condition, and adults with obesity and moderate to severe obstructive sleep apnea. Subcutaneous tirzepatide, once weekly, ongoing. A 2.5 mg starting dose for four weeks, then increases of 2.5 mg after at least four weeks at the current dose. Endpoint: the label states the escalation exists to reduce the risk of gastrointestinal adverse reactions, tells prescribers to consider a lower maintenance dosage when a higher one is not tolerated, and reports that the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time. Limitation: applies only to this FDA-approved product.
• Jastreboff et al., SURMOUNT-1, New England Journal of Medicine, 2022 (PubMed record, DOI 10.1056/NEJMoa2206038). https://pubmed.ncbi.nlm.nih.gov/35658024/. 2,539 adults with a BMI of 30 or more, or 27 or more plus a weight-related complication, diabetes excluded. Tirzepatide 5, 10, or 15 mg weekly or placebo, including a 20-week dose-escalation period. 72 weeks. Endpoint: the most common adverse events were gastrointestinal, most were mild to moderate, and they occurred primarily during dose escalation; adverse events caused discontinuation in 4.3%, 7.1%, and 6.2% of the tirzepatide groups against 2.6% on placebo. Limitation: an adverse-event pattern reported for one trial's escalation protocol, not a prediction for any individual, and not the schedules used for compounded products.
• Wilding et al., STEP 1, New England Journal of Medicine, 2021 (PubMed record, DOI 10.1056/NEJMoa2032183). https://pubmed.ncbi.nlm.nih.gov/33567185/. 1,961 adults with a BMI of 30 or greater, or 27 or greater plus a weight-related coexisting condition, without diabetes. Semaglutide 2.4 mg weekly or placebo, plus lifestyle intervention. 68 weeks. Endpoint: mean body-weight change of 14.9% against 2.4% on placebo; nausea and diarrhea were the most common adverse events, typically transient and mild to moderate, with 4.5% discontinuing for gastrointestinal events against 0.8% on placebo. Limitation: describes the branded product's titration design and trial population, not compounded dosing protocols.

Educational content only. Not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, changing, or stopping any medication, peptide, or supplement.